Managers
FLX Distribution has closed a USD2.5 million seed round, named two leading industry executives to its new Board of Directors, and added to its existing Advisory Board. “The FLX vision of a new model of distributing investment offerings to wealth managers and financial advisors is a reality as we welcome new investors to our company, add to our stable of board-level executives, and add asset managers and distribution professionals to our platform,” says Brian Moran, FLX Founder and Chief Executive Officer. “The industry overall and end-user investors will benefit as FLX adds accessibility, entrepreneurial drive, and complete flexibility to the investment
RedBird Capital Partners has entered into a definitive agreement with Toulouse FC to acquire an 85 per cent majority stake in the French Ligue 2 football club.
Toulouse FC was relegated, along with Amiens, from the top tier of French football in April when clubs voted to end the season early due to the coronavirus pandemic.
Founded by Gerald Cardinale, RedBird has over USD4 billion of equity under management. Its investment partners have included the New York Yankees, the Dallas Cowboys and the United States Women’s National Soccer Team.
Toulouse owner Olivier Sadran has stepped down as majority owner and President, but will retain
Vital Capital has partnered up with the US Government’s Kenya Investment Mechanism to provide funding to Kenyan agri-businesses that have been affected by the Covid-19 pandemic.
Vital Capital is an impact investment private equity fund focused on companies in sub-Saharan Africa. “We are excited to launch this major collaboration to support Kenyan agribusinesses in what is an incredibly challenging economic environment,” said Nimrod Gerber, managing partner of Vital Capital.
KIM is a five-year program funded by the US Agency for International Development (USAID) to unlock financing to businesses that have been hit by the global pandemic.
Vital Capital and
GED Capital (GED), an independent private equity group specialised in the Spanish lower mid- market, and Oquendo Capital, a firm that specialises in flexible capital and private debt for Spanish lower mid-market companies, have reached an agreement on the terms of a sale of Gestión Tributaria Territorial (GTT) to AnaCap Financial Partners (AnaCap), a specialist European financial services private equity and credit firm, subject to regulatory approval.
The existing management structure will remain in place as key long-term shareholders, partnering with AnaCap through GTT’s next phase of growth. Terms of the transaction were not disclosed. GTT is a specialist in the design
Software and technology-focused private equity investor Thoma Bravo is to acquire Majesco, a provider of cloud insurance software solutions for insurance businesses, in a deal valuing the company at USD594 million. Following the closing of the transaction, Majesco will operate as a privately held company.
Under the terms of the agreement, all Majesco shareholders of record will receive USD13.10 in cash for each share of Majesco common stock upon closing of the transaction. The price represents a premium of approximately 74 per cent over Majesco’s average closing price during the 30-trading day period ended 17 July, 2020.
The proposed merger is
Roslin Technologies, the UK’s specialist AgriTech venture builder, has invested in Singapore-based Protenga, a business which farms black soldier fly insects to produce animal feed and fertiliser. As part of Roslin Technologies’ ambitious programme, a bespoke genetic nucleus facility is being built near its HQ, which will focus on applying enhanced breeding technologies to develop improved insect lines together with Protenga for the global market.
These investments align with Roslin Technologies’ focus on developing alternative protein sources to help overcome the impending global food deficit and are central to Protenga’s mission to provide sustainable food sources to livestock, aquaculture and
KPS Capital Partners (KPS), through a newly formed affiliate, has entered into an asset purchase agreement to acquire substantially all of the assets of Briggs & Stratton, including equity of foreign subsidiaries, for approximately USD550 million.
Briggs & Stratton has filed a motion with the United States Bankruptcy Court for the Eastern District of Missouri seeking the designation of KPS as the stalking horse bidder in a sale motion as part of the Company’s filing of voluntary petitions under Chapter 11 of the Bankruptcy Code today. Briggs & Stratton expects to sell its assets through a court-supervised sale process under
Aquiline Capital Partners, a global private investment firm specialising in financial services and technology, has closed its investment in Quintes Holding, one of the largest independent insurance brokers in the Netherlands.
Since its founding in 2012, Quintes has built a national footprint of brokers with a focus on serving the Dutch SME sector.
The Company will maintain its corporate headquarters in Culemborg under the continued leadership of the existing management including CEO Gijsbert van de Nieuwegiessen and CFO Alex Klooster.
“The Dutch insurance market presents significant opportunities for continued growth, M&A activity and the need for a dedicated,
Omnes-backed Intys has acquired Univers Retail, a management and operational strategy consulting firm, specialised in distribution and retail. This is the first acquisition completed by the Belgian consultancy firm since Omnes invested in the company in July 2019.
Based in Brussels, Intys is one of the leading consulting firms in Belgium. As a multi-specialist player, Intys has a recognized expertise in the healthcare, energy, industrials and financial services sectors. Its 80 clients include leading companies and institutions in Belgium, Luxembourg and France. The firm generated a EUR35 million turnover in 2019 and has a staff of 360.
Based in
British Patient Capital has invested USD65 million in SV Health Investors’s USD265 million fund, SV7 Impact Medicine Fund (IMF), which is dedicated to investing in biotech companies.
The IMF is SV’s first biotech fund. It will aim to turn scientific breakthroughs into biotech companies producing high impact precision medicine drugs for poorly treated diseases.
So far the fund has invested in UK-based Alchemab, which develops antibody therapies for diseases including cancers, infectious diseases, and neurodegenerative conditions.
Cancer Research UK launched a partnership with SV Health Investors in June 2019 to focus on speeding up the translation of the organisation’s research
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
